publication date: Jan. 15, 2021

Conversation with The Cancer Letter

Sean Khozin named CEO of CancerLinQ: AI is here, and it will become even more democratized

Sean Khozin

Sean Khozin, MD, MPH

Global head, Data strategy and data science innovation,

Janssen R&D


Sean Khozin, a data science expert and formerly a senior medical officer at FDA, has been tapped to lead CancerLinQ—the American Society of Clinical Oncology’s multimillion-dollar big data initiative designed to generate real-world evidence from patient records.

Khozin will step into the role Feb. 16, replacing Cory Wiegert, who has served as CancerLinQ’s CEO since 2018. Wiegert was named chief operating officer at Integra Connect.

“The sky’s the limit here, because I think as AI continues to find its way into mainstream software applications and architecture—with hardware becoming ever more affordable—what will differentiate impactful organizations from the rest would be creativity and mission—features that I closely associate with CancerLinQ,” Khozin said to The Cancer Letter.

Khozin is currently global head of data strategy and data science innovation at Janssen R&D, a subsidiary of Johnson & Johnson, where he leads a multidisciplinary team charged with implementing data science solutions to support the development of innovative medicines.

Prior to joining Janssen, Khozin was acting associate director of the Oncology Center of Excellence at FDA, where he led the center’s bioinformatics, regulatory science, and clinical trial innovation efforts. He was also the founding executive director of Information Exchange and Data Transformation (INFORMED), FDA’s first data science and technology incubator.

Continue reading Sean Khozin named CEO of CancerLinQ: AI is here, and it will become even more democratized
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2021 The Cancer Letter Inc.